NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report sent to investors on Friday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets cut their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 2.1 %

Shares of NBY opened at $0.63 on Friday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The business’s fifty day moving average is $0.64 and its 200 day moving average is $0.62. The stock has a market cap of $3.08 million, a P/E ratio of -0.01 and a beta of 0.67.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.